Core U.S. Patents for Opdivo
Opdivo (nivolumab), Bristol Myers Squibb's PD-1 inhibitor for cancers like melanoma and lung cancer, has multiple patents listed in the FDA's Orange Book. The primary composition-of-matter patent, US 8,008,449 (covering the anti-PD-1 antibody), expires on October 11, 2033, after pediatric exclusivity extension.[1][2]
Key other patents include:
- US 8,779,108 (dosing regimen): Expires June 26, 2031.
- US 9,220,776 (crystalline forms): Expires December 5, 2032.
- Formulation patents like US 10,577,392 extend to 2034.[2]
BMS holds over 300 Orange Book patents and exlusivity until 2033, blocking generics until at least then.[1]
When Do Patents Expire in Other Countries?
European Patent EP1988947 expires June 12, 2027, but supplementary protection certificates push it to 2031-2033 in major markets like Germany and UK.[2] In Japan, core patents end around 2028 with extensions to 2032.[1]
Can Generics or Biosimilars Launch Before 2033?
No full generics yet due to biologics status—Opdivo requires FDA approval via BLA, not ANDA. Biosimilars face patent thickets; first U.S. litigation settled for 2032 entry (e.g., Samsung Bioepis).[3] Over 20 Paragraph IV challenges filed since 2021, with settlements delaying launches to 2031-2034.[1][2]
Why Multiple Expiry Dates?
Patents cover antibody sequence, manufacturing, formulations, and methods-of-use. Earliest expiries (2027 EU) target specific claims, but evergreening via new patents delays competition. Pediatric exclusivity adds 6 months to key dates.[2]
Impact on Pricing and Access
Opdivo lists at $12,000+ per dose; post-patent, biosimilars could cut costs 20-30% initially, based on other PD-1s like Keytruda.[3] Medicare price negotiation under IRA caps at $10,400/dose from 2028.[1]
[1]: DrugPatentWatch.com - Opdivo Patents
[2]: FDA Orange Book - Nivolumab
[3]: BioSpace - Opdivo Biosimilar Settlements